Ratings Aarti Drugs Limited

Equities

Market Closed - Bombay S.E. Other stock markets 03:52:10 16/07/2025 pm IST			5-day change	1st Jan Change
518.50 ^INR	-2.19%		+9.13%	+12.56%

07/05	Aarti Drugs Consolidated Net Profit Jumps in Fiscal Q4	MT
07/05	Aarti Drugs Limited, Q4 2025 Earnings Call, May 07, 2025

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
According to MSCI, the company's ESG score for its industry is poor.

With a 2025 P/E ratio at 33.45 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Source: Surperformance

Source: MSCI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Capi.($)
AARTI DRUGS LIMITED	-	-	57Cr
ELI LILLY AND COMPANY			69TCr
JOHNSON & JOHNSON			37TCr
ABBVIE INC.			33TCr
NOVO NORDISK A/S			30TCr
ROCHE HOLDING AG			26TCr
NOVARTIS AG			23TCr
ASTRAZENECA PLC			22TCr
MERCK & CO., INC.			20TCr
AMGEN INC.			16TCr
Average			27.65TCr
Weighted average by Cap.